ArticleDrug safety - case reports2016
Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine.
Article in Drug safety - case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Identifying Genetically Inferred Effects Linking Posttraumatic Stress Disorder to Women's Health, Lipid Disorders, and Malaria Medications.The American journal of psychiatry · 2024Article
- Sleep and PTSD in the Military Forces: A Reciprocal Relationship and a Psychiatric Approach.Brain sciences · 2021Review
- Bias and Confounding in Studies of Chronic Mental Health Effects from Mefloquine Exposure.The American journal of tropical medicine and hygiene · 2019Article
- Measurement of Mefloquine Exposure in Studies of Veterans' Sleep Disorders.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Psychomotor Agitation Following Treatment with Hydroxychloroquine.Drug safety - case reports · 2017Article
- A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions.Pharmacology research & perspectives · 2017Article
- Misclassification and Bias in Military Studies of Mefloquine.The American journal of tropical medicine and hygiene · 2017Article
- Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.Drugs in R&D · 2017Article
- Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 32-year-old male developed neuropsychiatric symptoms 2 weeks after starting mefloquine 250 mg/week for malaria prophylaxis. He continued to take the medication for the next 4 months. Initial symptoms included vivid dreams and anxiety, as well as balance problems. These symptoms persisted and progressed over the next 4 years to include vertigo, emotional lability, and poor short-term memory, which have greatly affected his personal and professional life. An extensive evaluation revealed objective evidence supporting a central vestibulopathy. These symptoms have been unresponsive to pharmacologic therapy and psychotherapy. A Naranjo assessment score of 6 was obtained for his initial symptoms, indicating a probable adverse drug reaction to mefloquine given the relationship between the clinical picture and drug exposure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.